• Pure Extracts upsizes private placement to total 16,900,000 special warrants at price of $0.505.
• PULL also received approval from OTC Markets, is trading on OTC Market under ticker symbol PRXTF.
• Trading under new OTC ticker is “major step forward,” says Company CEO.

Pure Extracts Technologies (CSE PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company, has increased its non-brokered private placement offering of special warrants; the original offering was announced on Dec. 16, 2020. The company also received approval from OTC Markets and is now trading on the OTC Market under the ticker symbol PRXTF.

The Company observed that the upsized private placement comprises 16,900,263 special warrants at a price of $0.505, which would result in gross proceeds for the Company of an estimated $8,534,632. The announcement explained that the Company anticipated using the proceeds from the placement for expanding the capacity of its extraction business as well as for general working capital.

Regarding trading on the OTC Market, Pure Extracts’ CEO Ben Nikolaevsky noted that “Trading under the new OTC ticker symbol PRXTF and applying for DTC eligibility is a major step forward in making it materially easier to welcome U.S.-based investors as new shareholders. This is an important step in amplifying our story to a wider audience and to grow our investor base.”

OTC Markets offer developing Canadian companies the opportunity to be publicly traded in the United States at lower cost and complexity than a U.S. exchange listing. Streamlined market standards allow Canadian companies to provide a strong baseline of transparency to inform and engage U.S. investors. To receive approval to trade on the OTC Markets, Canadian companies must be up-to-date in their SEDAR reporting and undergo regular verification and management certifications. Pure Extracts’ shares will continue to trade on the Canadian Securities Exchange (“CSE”) under the symbol ‘PULL’.

These announcements are indicative of Pure Extracts’ focus to strengthen and grow its presence in the cannabis, hemp and functional mushroom sectors as it leverages its expertise in extraction processes (https://ibn.fm/k2wpB). The Company’s forward-thinking strategy aligns with existing infrastructure and includes plans to develop high-bioavailable products and novel delivery methodologies, including tinctures, pills, capsules and edibles. One such venture, initiated in December, is its functional mushroom wellness business, which entails a process through which the active ingredients in mushroom biomass is concentrated into capsules and tinctures.

“Moving into the field of mushroom extractions is an obvious and exciting opportunity to leverage our advanced technology and proven capabilities,” said Nikolaevsky (https://ibn.fm/aP9p2). “We look forward to launching our functional products commercially within the next few months and can’t help but see the similarities to the cannabis sector regarding the pathways to both medical and recreational legalization. I believe our ability to immediately begin working in this burgeoning sector will create immense value for our business, our stakeholders, partners and shareholders alike.”

Headquartered just north of Whistler, British Columbia, Pure Extracts is a publicly listed, plant-based, extraction company that appears ideally positioned to be one of the dominant extraction companies in the rapid development and commercialization of functional mushroom and medicinal psychedelic products.

For more information, visit the company’s website at www.PureExtractsCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to PULL are available in the company’s newsroom at https://ibn.fm/PULL

• Company will initiate a Phase II adult trial for Berubicin this year focused on patients with glioblastoma multiforme
• WPD, a CNS sub-license partner, will be commencing a parallel Phase II adult trial and the first-ever pediatric Berubicin trial
• Additional clinical trials are in the pipeline, including one for the company’s newest drug candidate, WP1244, and its effects on central nervous system tumors

Biopharmaceutical company CNS Pharmaceuticals (NASDAQ: CNSP) recently took part in the H.C. Wainwright Bioconnect 2021 Virtual Conference, which took place January 11-14, 2021. CNS’s CEO John Climaco gave a presentation at the event, discussing how the clinical-stage biopharmaceutical company is developing novel treatments for primary and metastatic cancers of the brain and central nervous system (https://ibn.fm/7zYST).

CNS’s lead drug candidate is Berubicin, an anthracycline that, based on clinical data, can cross the blood-brain barrier in adults and reach the tumor cells of patients with brain cancer. As an organ targeted therapeutic, Berubicin demonstrated one durable complete response (not detectible on imaging) in a Phase I trial completed by Reata Pharmaceuticals, Inc. (NASDAQ: RETA) 14 years ago. CNS currently holds the worldwide exclusive licensing to the Berubicin drug and it recently obtained Investigational New Drug designation for it from the Food and Drug Administration.

In addition to Berubicin, the company’s current developmental pipeline includes a second promising drug candidate, WP1244. Licensed from The University of Texas MD Anderson Cancer Center in the first quarter of 2020, WP1244 is a DNA-binding agent that represents a novel class of potential therapeutics.

WP1244 is designed using anthracycline and distamycin-based scaffolds, creating small molecule agents binding extended sequences of DNA. In vivo testing demonstrated high uptake with WP1244 in the brain and subsequent antitumor activity in orthotopic models of the brain. The drug candidate is believed to be 500 times more potent than daunorubicin in inhibiting tumor cell proliferation. CNS entered into a Sponsored Research Agreement with MD Anderson Cancer Center in May 2020, related to WP1244.

CNS Pharmaceuticals, in partnership with company sublicensee WPD Pharmaceuticals, Inc. (CSE: WBIO) (FSE: 8SV1) currently has several clinical trials in different stages of preparation, including three glioblastoma multiforme (“GBM”) studies for Berubicin, scheduled to begin in Q1 2021. These include a randomized, controlled Phase II trial in the United States and another Phase II in Poland, conducted by WPD. Both these studies will be conducted with adult candidates. WPD will also begin the first-ever Phase I pediatric trial with Berubicin in Poland. Other studies in the pipeline for a future date include a potential Phase I trial for Berubicin with pancreatic and ovarian cancer and lymphoma patients as well as a potential Phase I trial for WP1244 for central nervous system tumors.

The primary focus for Berubicin has been patients with GBM, one of the most aggressive forms of brain cancer currently considered incurable. Each year, nearly 15,000 new GBM patients are being diagnosed in the United States. With the optimal therapy (surgical resection, chemotherapy, radiation), the median survival rate is only 15-23 months. Nearly 100% of GBM tumors recur after first-line therapy.

The Phase II trials for Berubicin in adult candidates are designed to be:

• Adaptive – the trial is designed to allow for modifications based on accumulated data from trial subjects
• Randomized – the trial randomizes which patients receive Berubicin versus the control group, eliminating the bias and increasing statistical significance
• Controlled – a control arm receiving the standard of care to compare the effectiveness of Berubicin against this standard, increasing the statistical significance
• Potentially Pivotal – the trials are designed to provide, pending positive results, the data necessary to support CNS’s request to the FDA for an expedited pathway to further development or approval of Berubicin

CNS believes that Berubicin has the potential to become a standard of care for GBM and other forms of brain cancer. The current first-line therapy includes temozolomide (“TMZ”). Nearly 40% of patients are genetically predisposed to respond to, becoming resistant to the treatment quickly. Berubicin could potentially be a second-line drug in these cases. The remaining 60% of patients may not be affected by TMZ, making Berubicin a potential first choice.

At the close of the presentation, Climaco said the company expects to see the first data for the Phase II trial in Poland reported during the third or fourth quarter of this year.

For more information, visit the company’s website at www.CNSPharma.com

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• Green Hygienics poised to become most highly certified hemp company in industry to differentiate itself from competition
• Anticipating tightening of regulatory standards, GRYN already achieved FDA registration and USDA/CCOF certification proving highest standards of product quality, transparency and safety
• With certifications to prove high-quality products, Green Hygienics appears ideally positioned to offer growth potential in increasingly quality-aware market

As an innovative technology-driven enterprise, Green Hygienics Holdings (OTCQB: GRYN) is dedicated to delivering the highest operating standards of industrial hemp cultivation and processing, and manufacturing of pharmaceutical-grade bioactive cannabinoids. Poised to bring safe and consistent products to market and thus change the industry’s landscape and enhance consumer confidence, GRYN is committed to becoming the most highly certified hemp company in the industry (https://ibn.fm/GVl6o). Last year was a year of success for Green Hygienics as the company achieved important milestones that lie at the heart of its value proposition. The first is registration with the U.S. Food and Drug Administration, which enhances GRYN’s core mission to provide processing and product safety, transparency and reliability both to consumers and the pharmaceutical industry. The second is the USDA Organic Certification (7 CFR Part 205) issued by the California Certified Organic Farmers, which allows Green Hygienics to cultivate and process post-harvest industrial hemp and supply certified organic hemp products to national and international markets from its Sol Valley Ranch property. With its 824-acre hemp farm, including 400,000 square feet of indoor greenhouse space, GRYN has become the largest single USDA-certified organic hemp farm in North America (https://ibn.fm/R8bLj). Green Hygienics appears ideally positioned to remain on the research-based innovation path and drive new product commercialization fully complaint to USDA and FDA regulatory requirements. The company intends to rationally design and deliver novel fit-for-purpose cannabinoids and targeted bio-delivery technologies, using cutting-edge technology to solve the issues of product stability, pharmacokinetics, biological tissue distribution and systemic bioavailability to improve the lives of billions. With an emerging push in the market as consumers ask for safe and efficacious products while industries such as medical, nutraceutical and pharmaceutical are seeking a secure supply chain, product quality and product associated evidence-based functionality become strong differentiators among medical practitioners and customers. The company that can address these unmet market needs could be well-placed to secure a strategic advantage in the marketplace and Green Hygienics looks poised to achieve precisely that and to become a leader in compliances and capabilities in the hemp and cannabinoid supply marketplace. As GRYN intends to become the most highly certified hemp company in the industry, it presents investors with an opportunity to invest in a company that uniquely positions itself as a trusted source that delivers safe and premium quality products to consumers and to CPG (consumer-packaged-goods) and pharmaceutical companies. With certifications to prove the highest operating standards, Green Hygienics seems well-positioned to offer growth potential in a market that is becoming increasingly quality-aware. For more information, visit the company’s website at www.GreenHygienics.com. NOTE TO INVESTORS: The latest news and updates relating to GRYN are available in the company’s newsroom at http://ibn.fm/GRYN

• Research shows that market for agricultural biopesticides expected to grow rapidly at CAGR of 14.7% until 2025
• MustGrow providing natural plant-based biopesticide solutions for protecting plants from pests and diseases, utilizing the natural defense mechanism of the mustard plant
• Company seems well positioned within biopesticides market expected to achieve fastest growth

The market for agricultural biopesticides is growing rapidly. The latest Markets and Markets report estimated the industry was valued at $4.3 billion in 2020 and is projected to almost double its size in the next five years — reaching $8.5 billion by 2025 and growing at a CAGR of 14.7% during the same period (https://ibn.fm/26NNm). MustGrow Biologics (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) is well placed to capitalize on this opportunity, backed by the changing market landscape that increasingly favors natural solutions to protect agricultural crops. MustGrow’s organic biopesticide approach is plant based — harnessing the mustard seed’s natural defense mechanism to control diseases, pests and weeds.

According to the report, the use of “synthetic chemicals can lead to pollution and contamination of the soil as well as can have. . . harmful effects on the food chain.” Because of this, the report observes, there has been increasing awareness of residue-free food and a high interest in biological products.

With the change in eating habits, farmers are pressurized to shift to adopt a sustainable method of farming. Fruit and vegetable cultivation requires more investment, and with the huge infestation in fruits and vegetables both in open fields and green-houses, the demand for biopesticides is increasing. Also, to meet the export demand for residue-free crops, farmers are implementing the use of biopesticide in combination with conventional chemicals. The trend in the consumption of organic crops is also pushing farmers to adopt biopesticides.

Along with a greater awareness of biopesticides has come increasing demand for organic-grown food. “The acreage under organic cultivation for fruits and vegetables is also increasing,” the report noted. “And to achieve the standards prescribed by international exports, farmers are adopting the usage of biopesticides. To combat the harmful effects of synthetic pesticides, the government is taking initiatives in various regions by emphasizing the use of integrated pest management. Strategic developments such as expansions, new product launches, collaborations, and agreements have been adopted by the majority of key players to strengthen the market.”

The report projects that within the whole biopesticides space, the bioinsecticides segment is expected to dominate the market during the forecast period, and the fruits and vegetable segment is expected to achieve the fastest growth. The increasing pest resistance and the resurgence of crops require sustainable solutions amid regulatory ban and phase-out of some of the main ingredients.

Because of their “favorable” properties, bioinsecticides are positioned as an adequate response — they do not leave residues in the products, and they do not harm natural pests’ enemies or the environment. According to the report, the North American region is expected to drive the growth of the international biopesticides market.

The change in market demanding residue-free and organic food combined with the ever-more stringent regulatory standards in the international agricultural food supply chain is pressuring farmers to adopt a sustainable method of farming using biopesticides. As a company that operates in the robust segments of the growing biopesticides space, MustGrow is ideally positioned to benefit from these market forces.

This agriculture biotech company, which is focused on providing natural science-based biological solutions for high-value crops such as fruits and vegetables, appears poised to leverage the growing momentum favoring alternatives to synthetic chemicals. As global agriculture looks to move closer to sustainable ways of boosting yields and crop protection, MustGrow continues to position itself as an essential part of the food landscape of the future with its mustard plant-based biopesticide.

For more information, visit the company’s website at www.MustGrow.ca.

NOTE TO INVESTORS: The latest news and updates relating to MGROF are available in the company’s newsroom at https://ibn.fm/MGROF

• Rapidly growing cannabis market evolving to include diverse clientele seeking unique strains
• PACR uses genetics-first approach to cultivate exclusive high-yield strains with varying cannabinoid profiles
• PACR catalog features 350 tested cultivars, including 50 super-elite strains prized for unique properties

Smoking marijuana decades ago traditionally meant rolling one type of cannabis that was grown outdoors under mostly natural conditions. Decades later, the market has completely transformed to accommodate the needs of savvy consumers who understand different strains and their varying effects. PacRoots Cannabis (CSE: PACR) (OTCQB: PACRF), a Canada-based cannabis company dedicated to producing premium-quality strains and products through a genetics-focused approach, is positioned to benefit from this market shift with roughly 350 tested cultivars in its extensive catalog, which includes 50 super-elite strains prized throughout the industry for their unique therapeutic properties. Marijuana strains are typically differentiated by their color, smell, taste and cannabinoid profile – the latter being the phytochemical composition specific to the plant. Specialized cultivation and strain development is undertaken by many growers seeking to leverage specific properties of the plant in order to produce specialized strains for specific markets—markets which include both medical and recreational users. The result of this innovation in cannabis cultivation has been a boom in branded cannabis strains, evidenced by increased brand recognition among loyal, repeat customers at legal dispensaries (https://ibn.fm/iq8Ca). PACR is positioned to benefit from these emerging markets by providing retailers with high-quality strains tailored for specific uses. The company’s genetics-based approach to cultivation has produced prized strains with varying amounts of tetrahydrocannabinol (“THC”) and cannabidiol (“CBD”) – two of over 140 known cannabinoids in the cannabis plant that can produce different effects on the body. Along with altering the cannabinoid profile of its strains, the company also leverages genetic technology to develop plants that thrive in different climatic conditions for maximum yields each season. PACR has a competitive advantage in the industry through its strategic licensing agreement with Phenome One Corp, a privately-held full-service genetics cannabis company that gives PACR access to one of the largest living genetic cannabis libraries in Canada. This valuable, unparalleled resource has enabled the Company to diversify its product catalog to include hundreds of cultivars and dozens of elite strains offering specialized beneficial characteristics unique to the market. The cannabis market has evolved from small-time dealers on street corners to an entire industry with differentiated products and discerning, knowledgeable consumers. PACR is leveraging this market shift through a genetic-first approach to cultivation that produces first-in-class high-yield strains which appeal to a wide variety of consumers across the rapidly growing legal cannabis market. For more information, visit the company’s website at www.PacRoots.ca. NOTE TO INVESTORS: The latest news and updates relating to PACR are available in the company’s newsroom at http://ibn.fm/PACR

• Imagin Medical Inc. successfully weathered the 2020 pandemic-induced economic challenges and transitioned its surgical visualization product, the i/Blue Imaging System(TM) from the development stage to manufacturing  and has  after
• Imagin’s next stage will be supported by a $3 million convertible note, with the final funding tranche expected to close this quarter
• The i/Blue Imaging System combines the advantages of blue light with advanced optic and light sensors to address the limitations of both white and blue light imaging to help surgeons better visualize and remove cancerous cells. The system uses a contrast agent to highlight the cancer and projects both the white and blue light images side-by-side simultaneously on the surgical monitor
• Bladder cancer is the sixth most prevalent cancer in the U.S., the third most common cancer in men, more than 17,000 deaths are expected in the U.S. this year due to bladder cancer
• Once Imagin obtains final FDA approval and finishes rolling out its product, the company expects to expand its product line by adapting its IP for use with multiple contrast agents for use in other minimally invasive surgeries

Following an unusual series of hardships for North America, as well as the world at large, during the past year, people are beginning to see reasons for optimism that 2021 will deliver better economic news, less political unrest and an overall reversal of the COVID pandemic’s persistently climbing death and disability toll.

Imagin Medical (CSE: IME) (OTCQB: IMEXF), has achieved significant milestones during 2020 despite the obstacles posed by COVID and other adverse factors. Imagin’s strategy has positioned the company for greater strides in the coming year as socio-economic conditions improve.

Imagin’s proprietary i/Blue Imaging System is designed to significantly enhance surgeons’’ability to visualize and remove cancer cells using blue light by combining advanced optics and light sensors with a contrast imaging agent. A key feature is the system’s adaptability to almost any scope already in use by hospitals and surgical centers.

But the company was compelled to cut salaries and reduce expenses in all areas of the business during 2020 in order to extend its financial runway for duration of the pandemic, while also transitioning to online meeting technology that better enabled Imagin to safeguard the health and wellbeing of its employees.

Despite the difficulties, Imagin was able to transition its product from the development stage to manufacturing — contracting with Lighthouse Imaging, an FDA registered and ISO 13485:2016-certified manufacturer. The contract will help propel Imagin toward completion of its final pre-production stage and finalize test parameters that meet exacting FDA requirements for live-use surgical imaging equipment., according to a news release issued by the company (https://ibn.fm/Th7Nr).

“Our relationship with Lighthouse Imaging marks a new stage in the company’s progress,” Imagin President and CEO Jim Hutchens stated. “We anticipate 2021 to be a breakout year with emphasis on manufacturing and the FDA process.”

The product preparation for broad manufacturing, as well as FDA approval and marketing procedures, will be funded largely by a $3 million convertible note undertaken by Imagin during the final months of 2020. The company has closed on the first of four tranches and expects to execute the final tranche this quarter, according to the news release.

Imagin will also work to develop expanding support from the medical community, in part through its participation at the 2021 American Urology Association (“AUA”) annual meeting. Imagin considers the AUA conference to be very significant marketing and networking opportunity that, much to their frustrations, was cancelled last year due to the pandemic (https://ibn.fm/gvrX1).

Imagin’s current technological approach is to help combat bladder cancer during minimally invasive surgery with advanced imaging abilities. Bladder cancer is the fourth most common cancer in men and one that is expected to directly result in more than 17,000 deaths this year in the United States, with similar numbers expected for 2021 (https://ibn.fm/R864t). Providing more precise visualization than white light, blue light cystoscopy infuses the bladder with a contrast agent that highlights the contours of the cancer. To resect, however, surgeons must use the real-time white light image, requiring them to switch back and forth to locate and then remove the cancer. The i/Blue Imaging System provides the option to display, in real-time, the white and blue light images side-by-side simultaneously, eliminating the need to switch back and forth resulting in a more efficient and effective procedure.

Eventually, Imagin expects to expand its IP for use with other contrast agents and minimally invasive surgeries, such as laparoscopic (general and gynecological), colorectal and thoracic interventions.

For more information, visit the company’s website at www.ImaginMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

• UME commited to offering high-quality COVID-19 services, solutions and supplies.
• To effectively end worldwide pandemic, systematic screening and detection of both clinical and asumptomatic COVID-19 tests is critical.
• CareStart antigen test features 10-minute processing time, identifies acute infection, helps provide critical answers.

Despite approval and rollout of COVID-19 vaccines, experts agree that even as the pandemic dies down in the coming months, SARS-CoV-2, the virus that causes the infectious disease, is likely here for the long haul (https://ibn.fm/1idh8). United Medical Equipment Business Solutions Network (“UME”) is here for the long haul too, commited to offering high-quality COVID-19 services, solutions and supplies. Among the supplies UME currently provides is the CareStart(TM) COVID-19 Antigen Rapid POC test.

Before COVID-19 was even declared a pandemic, the CareStart COVID-19 Antigen test had been authorized for use by the Federal Drug Administration (“FDA”) under an Emergency Use Authorization (“EUA”). “Due to the highly contagious nature and global spread, SARS-CoV-2 . . . continues to have devastating impacts on healthcare systems and the world economy, including the U.S.,” states CareStart COVID-19 Antigen packaging material approved by the FDA (https://ibn.fm/BIVxs).

“To effectively end the SARS-CoV02 pandemic, systematic screening and detection of both clinical and asumptomatic COVID-19 tests is critical,” the information continues. “Particularly, the identification of subclinical or asymptomatic cases is important to reduce or stop the infection because these individuals may transmit the virus. As a point-of-care test with a 10 min testing time, CareStartCOVID-19 Antigen test allows effective screening of COVID-19 infection on a large scale.”

The CareStart antigen test can be administered by authorized laboratories and at the point of care by medical professionals to detect the presence of the SARS-CoV-2 nucleocapsid protein antigen (https://ibn.fm/qCkqU). The innovative test features a 10-minute processing time, identifies acute infection with 88.4% sensitivity and 100% specificity, and helps provide critical answers about active infections to patients and healthcare workers alike.

The CareStart product is part of a UME’s comprehensive COVID-19 monitoring strategy, which was carefully designed with the assistance of medical experts and includes ongoing, data-driven COVID-19 testing. United Medical Equipment Business Solutions is committed to being the leading provider of high-quality, reliable and transparent information and resources for all, particularly veterans and seniors. The company provides essential information and products that helps the community achieve optimal health and improve their quality of life.

In addition to the CareStart COVID-19 Antigen tests, UME provides a wide array of other COVID-19 supplies and products, including sanitizers, gloves and face shields, thermometers, hoods and masks.

UMEs’ mission is to provide guidance for caregivers, veterans, the aging population and the medical community through its robust medication management and telehealth applications. In addition, the company recognizes the importance of being socially responsible as a corporation by giving back to the world through emergency assistance grants awarded to seniors, with an emphasis on veterans, by supporting nonprofits in their missions, and by supporting the American economy by providing work-at-home opportunities.

To learn more about this company, visit www.UnitedMedSolutions.com.

NOTE TO INVESTORS: The latest news and updates relating to United Medical Equipment are available in the company’s newsroom at https://ibn.fm/UnitedMed

• Autonomous Security Robot (“ASR”) maker Knightscope offers a Machine-as-a-Service (“MaaS”) subscription that monitors, records and relays information according to business client needs
• Knightscope’s AI-enhanced robots patrol sites for Fortune 1000 companies, hospitals and police department clients, providing a sense of safety particularly in crime-prone areas
• The robots’ security features include 360-degree eye-level HD streaming video, obstacle recognition, face and license plate recognition, and thermal anomaly detection
• The Knightscope Security Operations Center (“KSOC”) allows operators to monitor real-time data produced by the robot patrols and to communicate with people through the robots’ Intercom and Broadcast system if necessary
• Market analysts foresee the ASR market growing with a CAGR of 7.93 percent between 2021 and 2026

Cautious optimism is driving economic forecasts for 2021 in the United States as market managers anticipate improving economic data and bullish investor sentiment but also the risks of a bumpy transition year if new COVID-19 pandemic containment policies stifle growth or pandemic-driven economic safety nets are terminated before the general public is ready to progress without them (https://ibn.fm/sQX21). Patient business leaders will continue to plan for their companies’ safety needs while hoping for the best possible outcomes of vaccine rollout efforts, a new national political administration and evidence that societal upheaval is prompting a recommitment to day-to-day stability measures. Autonomous robot manufacturer Knightscope is working to play a key role in making the United States a more secure place. Knightscope’s product platform involves a lineup of AI-driven patrols that can help companies manage transitions in workforce levels and reduce crime in areas affected by destabilization. The company’s products include robot sentries for a variety of business conditions. One robot monitors from a stationary platform while two other models rove the premises, designed for indoor or outdoor conditions as needed. The robots are designed to recognize obstacles in their path as they move about, but also potential obstacles to a safe environment for employees. They can provide alerts to business visitors about COVID policies, optional temperature scanning for fevers, landscape and perimeter inspection, and recordings of faces and license plates filmed with 360-degree live video. Clients have reported effective problem deterrence when using Knightscope’s Autonomous Security Robots (“ASRs”). A recent blog entry provided a few examples: One hospital network reported it was experiencing an average of two crimes per week. When a mobile ASR was deployed, the crime rate dropped to zero for the following 12 months. When a California police department introduced an ASR to a crime-prone public park, officers saw a 46 percent reduction in crimes and a 68 percent drop in citations. And when a San Francisco business deployed a robot in its parking structure, crimes dropped from an average of 20 per month to one over the course of 12 months (https://ibn.fm/p7Csy). The robots are delivered on a Machine-as-a-Service (“MaaS”) business model that features subscriptions with annual contracts. The robots operate 24 / 7 every day with an effective price of $4 to $11 per hour (https://ibn.fm/4qR9h). They are capable of recharging themselves at strategically located stations when their battery level begins to drop, and their Knightscope Security Operations Center (“KSOC”) allows operators to gain access to information in real-time circumstances. The global autonomous mobile robots market size is expected to reach $145.5 billion by 2026, rising at a market growth of 24.6 percent CAGR during that period, according to a recent report by ResearchAndMarkets.com (https://ibn.fm/u8qY3). Mordor Intelligence analysts anticipate that between 2020 and 2026, revenues for the global ASR market segment will rise from $2.44 billion to $3.91 billion, with a CAGR between 2021 and 2026 of 7.93 percent (https://ibn.fm/obKX1). For more information, visit the company’s website at www.Knightscope.com. Visit www.Knightscope.com/invest for a summary of Knightscope as an investment, with a blue Instant Messaging button for direct contact with their CEO. DISCLAIMER: You should read the Offering Circular and risks related to this offering before investing. This Reg A+ offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://ibn.fm/Knight

• Friendable Inc.’s Fan Pass platform attracted a roster of more than 700 artists in 2020
• Fan Pass is filling the void created by the live event shutdown necessitated by the COVID-19 pandemic
• New subscribers can check out the latest updates and releases from their favorite artists for free on a trial basis by downloading the Fan Pass app

Friendable (OTC: FDBL), a mobile technology and marketing company focused on connecting and engaging users through its proprietary mobile and desktop applications, kicked off the new year by issuing a recap of its milestones and achievements in 2020. In the news release, the company noted that artist sign ups for its innovative Fan Pass platform, which connects artists with fans through exclusive virtual channels, surpassed 700 last year. This total marked a significant ramp up following Friendable’s launch of the Fan Pass platform in late July 2020 with a debut event featuring 16 performers. “In a very short period of time following our release of Fan Pass we have continued to receive numerous items of validation while continuing to test new traction points, service offerings and scalability of our business model,” Robert A. Rositano Jr., CEO of Friendable, stated in the news release (https://ibn.fm/ua6la). “As we are focused on providing the very best experience for our artists and their fans, these spikes validate many of our efforts while providing additional and significant exposure for our brand.” The Fan Pass platform’s focus on live streaming and virtual events filled a sizable need in recent months as the entertainment industry has struggled to navigate and survive the sustained effects of the worldwide pandemic. The global live events sector has seen its income all but erased since March 2020, and this industry-wide shutdown is expected to continue well into 2021 (https://ibn.fm/muraw). In the absence of live events, concerts and gatherings, Fan Pass has provided an effective alternative ecosystem through which diehard followers and casual fans alike can support and develop lasting connections with a growing collection of artists. For artists, Fan Pass provides a number of advantages, particularly as the worldwide live entertainment market remains extremely limited. The platform’s intuitive design allows artists to invite fans and social followers from around the world to join in exclusive chats and experience virtual VIP meetups, interviews and behind-the-scenes content. The platform even allows artists to offer custom-designed merchandise to their growing fanbases. “We are very excited for 2021, as the live streaming video marketplace continues to lead the way into an entirely new model of in-person live events combined with the live, yet virtual, experience of performing on Fan Pass,” Rositano continued. “This is a year for scale on all fronts as we are confident our revenues will continue to scale as we perform, per our plan.” Fan Pass is free for new subscribers on a trial basis and is currently available for download on both the App Store and Google Play. Following the trial, subscriptions are billed at $3.99 per month, providing exclusive access to artists and their latest projects at a fraction of the cost of traditional face-to-face meetups. For more information, visit the company’s websites at www.Friendable.com or www.FanPassLive.com. NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL

• Company acquired seven gold projects in the mineral-rich Andes Mountains of Northern Chile, with three ready for drilling
• Epithermal deposits signify additional nearby and/or deeper strains of porphyry deposits
• Canada, Chile have maintained strong, stable relationship for nearly 80 years

The Canadian junior exploration company GoldHaven Resources (CSE: GOH) (OTCQB: GHVNF) has, in 2020, acquired low-risk, high-quality land in its search for new deposits of gold. As the company moves into 2021, new projects and phases of exploration are in the works.

As a junior gold mining company, GoldHaven has its eye on the price of gold and the jurisdictions’ stability with every project undertaken. The ability to read the market and navigate the fluctuations of the economy is essential. As a new undertaking, not bringing the right skill to the table on day one is a disaster waiting to happen. The GoldHaven team brings a wealth of experience and knowledge from having successfully worked within the mining industry and holding high-level positions in publicly traded mining companies; company executives have more than 100 years of combined experience in gold mining.

The goal of GoldHaven is to funnel that combined talent and expertise into projects that provide stability and de-risk the investment. To succeed, GoldHaven must identify and capitalize on valuable precious metal projects in mineral-rich districts within stable political jurisdictions.

In 2020, GoldHaven acquired seven gold projects located in the Maricunga Gold Belt in Northern Chile. To date, this mineral-rich land is known to host over 100 million oz. of gold, 450 million oz. of silver, and 13 billion lbs. of copper in resources (https://ibn.fm/Yu6Y7).

Gold mining in Chile dates back to the end of the 16th century. The current Chilean gold rush is due to the discovery of a series of subvolcanic gold deposits. These deposits, which are mainly epithermal, have mostly been found at elevations over 4,000 m in the Andean Cordillera, also known as the Andes Mountains (https://ibn.fm/eru0u). Epithermal deposits provide around 12% of the world’s annual gold production, the presence of which also indicates additional porphyry deposits nearby and at a greater depth (https://ibn.fm/gdTe3).

The Maricunga Belt lies between latitudes 26 degrees and 28 degrees south in the Andes of Northern Chile. According to the BBC, “Chile is one of South America’s most stable and prosperous nations. It has been relatively free of the coups and arbitrary governments that have blighted the continent” (https://ibn.fm/mvrm5).

Canada has had a close relationship with Chile for close to 80 years. The two countries share values that include democracy, human rights, open markets and more. The Canada-Chile Partnership Framework and the Canada-Chile Free Trade Agreement (“CCFTA”) have allowed companies such as GoldHaven to explore minerals and metals’ sustainable development. Chile is Canada’s top investment destination in South and Central America. Direct investment in Chile reached $21.5 billion at the end of 2018 (https://ibn.fm/TUWnG). It is a relationship that only continues to grow stronger and more stable with time.

While 2020 has proven to be a year of uncertainties, GoldHaven has risen to the challenge and navigated exploration and development with a talented management team. With the combined expertise of a seasoned team, mineral-rich projects, and assets in stable political jurisdictions, GoldHaven continues to offer security during uncertain times to investors.

For more information, visit the company’s website at www.GoldHavenResources.com.

NOTE TO INVESTORS: The latest news and updates relating to GHVNF are available in the company’s newsroom at http://ibn.fm/GHVNF